bioRxiv Science⌕ Search

Biology subjects

O'Bryant, S.

Publications and source records attributed to O'Bryant, S..

2 recordsLinked to original sources

White Matter Tract Vulnerability to Amyloid Pathology on the Alzheimer's Disease Continuum

Alzheimers disease (AD) is marked by progressive cognitive decline and memory loss, due to the abnormal accumulation of amyloid-beta (A{beta}) plaques, which facilitate the spread of tau pathology, and a gradually spreading pattern of neuronal loss. Understanding how amyloid positivity affects the brains neural pathways is critical for understanding how the brain changes with AD pathology. Tractometry offers a powerful approach for the in vivo, 3D quantitative assessment of white matter tracts, enabling the localization of microstructural abnormalities in diseased populations and those at risk. In this study, we applied BUAN (Bundle Analytics) tractometry to multi-cohort diffusion MRI data from a total of 1,908 participants: 606 participants in ADNI3 (Alzheimers Disease Neuroimaging Initiative Phase 3) and 1,302 participants from the HABS-HD (Health and Aging Brain Study-Health Disparities). Using BUAN and along-tract statistical analysis, we assessed the localized effects of amyloid positivity on white-matter pathways, which may be further influenced by downstream tau accumulation. Amyloid positivity was quantified via amyloid-sensitive positron emission tomography (PET). BUAN enables tract-specific quantification of white matter microstructure and supports statistical testing along the full length of fiber bundles to detect subtle, spatially localized associations. We present 3D visualizations of tractwise amyloid associations, highlighting distinct patterns of white matter degeneration in AD.

neuroscience↗

Brain-derived extracellular vesicle microRNAs in Lewy body and Alzheimer's disease

INTRODUCTIONRobust plasma-based biomarkers to distinguish Lewy body disease (LBD) and Alzheimers disease (AD) are currently lacking. We applied track-etch magnetic nanopore (TENPO) sorting for enrichment of brain-derived extracellular vesicle (EV) signatures as potential biomarkers to address this gap. METHODSWe analyzed plasma from 137 autopsy-confirmed patients [30 LBD, 31 AD, 30 AD/LBD, 19 AD with amygdala Lewy bodies (AD/ALB), and 27 controls], sequencing miRNAs from TENPO-isolated GluR2-positive (neuron-enriched) and GLAST-positive (astrocyte-enriched) EVs, and measuring plasma proteins (A{beta}40, A{beta}42, tau, p-Tau181, p-Tau231) via SIMOA. RESULTSWe identified 16 GluR2+, 8 GLAST+, and 4 protein biomarkers with differential expression (false discovery rate-corrected P value < .1) between LBD and AD. A multimodal 15-feature panel classified LBD versus AD with 10-fold cross-validated accuracy = 0.95 and area under the curve (AUC) = 0.96. DISCUSSIONBrain-derived EVs offer accurate and accessible miRNA biomarkers for the differential diagnosis of LBD and AD.

bioengineering↗